David A. Siegel Ocuphire Pharma, Inc. Transaction History
Two Sigma Advisers, LP
- $47 Billion
- Q3 2025
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Ocuphire Pharma, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 10,200 shares of OCUP stock, worth $9,996. This represents 0.0% of its overall portfolio holdings.
Number of Shares
10,200Holding current value
$9,996% of portfolio
0.0%Shares
6 transactions
Others Institutions Holding OCUP
# of Institutions
53Shares Held
19.2MCall Options Held
0Put Options Held
0-
Perceptive Advisors LLC New York, NY4.33MShares$4.24 Million0.01% of portfolio
-
Bios Capital Management, LP Fort Worth, TX3.68MShares$3.61 Million7.42% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT3.35MShares$3.28 Million0.13% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.34MShares$1.32 Million0.0% of portfolio
-
Mink Brook Asset Management LLC West Palm Beach, FL1.24MShares$1.21 Million1.38% of portfolio
About Ocuphire Pharma, Inc.
- Ticker OCUP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 20,579,800
- Market Cap $20.2M
- Description
- Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Its lead product candidate is Nyxol eye drops, a once-daily preservative-free eye drop formulation of phentolamine mesylate, which is in Phase III clinical tr...